Fundraising Fox

Cytimmune Sciences

Rockville, US · Delaware corporation

Biotech

Founders & leadership

LT
Lawrence TamarkinFounder
MS
Mitchell S. MarderExecutive
GR
Gary RosenfeldExecutive
JL
Jason LevineExecutive
GF
Giulio F. PaciottiNamed on SEC filing

Board

MS
Marc StanleyBoard director
NZ
Norman ZoberBoard director
JW
John W. HoladayBoard director
HK
Hidetaka Kentaro ItaniBoard director
RA
Robert AshtonBoard director
NC
Neal CohenBoard director
KB
Kenneth B. WhiteBoard director

Reported raises · per SEC filings

Form D private placements

$8.5M disclosed across 10 rounds · 2012–2020

▶$997.8KraisedDec 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David M. OarrExecutive Officer
  • Giulio F. PaciottiExecutive Officer
  • Mark D. GilbertDirector
  • Hidetaka Kentaro ItaniDirector
  • Ira ShapiroDirector
  • Marc StanleyDirector
  • Saba S. MalakExecutive Officer, Director
Offering amount
$3M
Amount sold
$997.8K
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50KraisedApr 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Hidetaka Kentaro ItaniDirector
  • Marc StanleyDirector
  • Ira ShapiroDirector
  • Gary RosenfeldExecutive Officer
  • David M. OarrExecutive Officer
  • Mark D. GilbertDirector
  • Saba S. MalakExecutive Officer, Director
Offering amount
$500K
Amount sold
$50K
First sale
Apr 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$75KraisedMar 2019 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ira ShapiroDirector
  • John W. HoladayDirector
  • Mitchell S. MarderExecutive Officer
  • Neal CohneDirector
  • Gary RosenfeldExecutive Officer
  • Lawrence TamarkinExecutive Officer, Director
  • David OarrExecutive Officer
  • Marc StanleyDirector
  • Hidetaka Kentaro ItaniDirector
Offering amount
$500K
Amount sold
$75K
First sale
Mar 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30KraisedOct 2017 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ira ShapiroDirector
  • Lawrence TamarkinExecutive Officer, Director
  • Gary RosenfeldExecutive Officer
  • Hidetaka Kentaro ItaniDirector
  • Mitchell S. MarderExecutive Officer
  • Neal CohenDirector
  • John W. HoladayDirector
  • Marc StanleyDirector
Offering amount
$2M
Amount sold
$30K
First sale
Oct 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100.8KraisedJan 2017 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mitchell S. MarderExecutive Officer
  • Marc StanleyDirector
  • Ira ShapiroDirector
  • Gary RosenfeldExecutive Officer
  • John W. HoladayDirector
  • Neal CohenDirector
  • Robert AshtonDirector
  • Lawrence TamarkinExecutive Officer, Director
  • Hidetaka Kentaro ItaniDirector
Offering amount
$3M
Amount sold
$100.8K
First sale
Dec 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$747.7KraisedAug 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Marc StanleyDirector
  • Norman ZoberDirector
  • Mitchell S. MarderExecutive Officer
  • Lawrence TamarkinExecutive Officer, Director
  • John W. HoladayDirector
  • Hidetaka Kentaro ItaniDirector
  • Robert AshtonDirector
  • Giulio F. PaciottiExecutive Officer
  • Neal CohenDirector
  • Gary RosenfeldExecutive Officer
Offering amount
$2M
Amount sold
$747.7K
Minimum investment
$100K
First sale
Aug 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$690KraisedSep 2014 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert AshtonDirector
  • Marc StanleyDirector
  • Mitchell S. MarderExecutive Officer
  • Giulio F. PaciottiExecutive Officer
  • John W. HoladayDirector
  • Neal CohenDirector
  • Lawrence TamarkinExecutive Officer, Director
  • Gary RosenfeldExecutive Officer
  • Hidetaka Kentaro ItaniDirector
  • Norman ZoberDirector
Offering amount
$1M
Amount sold
$690K
First sale
Sep 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$400KraisedMay 2014 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Hidetaka Kentaro ItaniDirector
  • Norman ZoberDirector
  • Mitchell S. MarderExecutive Officer
  • John W. HoladayDirector
  • Giulio F. PaciottiExecutive Officer
  • Marc StanleyDirector
  • Neal CohenDirector
  • Gary RosenfeldExecutive Officer
  • Lawrence TamarkinExecutive Officer, Director
  • Robert AshtonDirector
Offering amount
$1.2M
Amount sold
$400K
Minimum investment
$100K
First sale
May 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Rockville Maryland based Cytimmune Sciences is raising $3,000,000.00 in New Equity and Debt Financing. - intelligence360intelligence360.news · Jan 2021

Frequently asked questions

Who founded Cytimmune Sciences?
Cytimmune Sciences was founded by Lawrence Tamarkin.
How much funding has Cytimmune Sciences raised?
Cytimmune Sciences has disclosed $8.5M raised across 10 rounds.
Where is Cytimmune Sciences headquartered?
Cytimmune Sciences is headquartered in Rockville, US.